Karyopharm Therapeutics
KPTI
KPTI
77 hedge funds and large institutions have $102M invested in Karyopharm Therapeutics in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
43.31% more ownership
Funds ownership: 55.52% → 98.83% (+43%)
12% more funds holding
Funds holding: 69 → 77 (+8)
Holders
77
Holding in Top 10
–
Calls
$31.3M
Puts
$16.9M
Top Buyers
| 1 | +$14.9M | |
| 2 | +$14.6M | |
| 3 | +$10.6M | |
| 4 |
Goldman Sachs
New York
|
+$7.22M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$6.04M |
Top Sellers
| 1 | -$6.84M | |
| 2 | -$2.97M | |
| 3 | -$2.23M | |
| 4 |
EAM
Exome Asset Management
New York
|
-$2.18M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.04M |
